TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04971148

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HFNC flow set at patient peak tidal inspiratory flow
Description: HFNC flow will be set at the level equal to patient peak tidal inspiratory flow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFNC flow set at 1.33 times of patient peak tidal inspiratory flow
Description: HFNC flow will be set at 1.33 times of patient peak tidal inspiratory flow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFNC flow set at 1.67 times of patient peak tidal inspiratory flow
Description: HFNC flow will be set at 1.67 times of patient peak tidal inspiratory flow

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFNC flow set at 2 times of patient peak tidal inspiratory flow
Description: HFNC flow will be set 2 times of patient peak tidal inspiratory flow
Study: NCT05182359

Intervention type: OTHER
Group type: OTHER
Intervention: SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test
Description: The SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) test is used to predict the four-year likelihood of myocardial infarction, stroke, hospitalization for heart failure or death. It will be provided to the participant's ordering provider.

Intervention type: OTHER
Group type: OTHER
Intervention: SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test
Description: The SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) test is used to predict the four-year likelihood of myocardial infarction, stroke, hospitalization for heart failure or death. It will be provided to the participant's ordering provider.
Study: NCT03326128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion Hydrochloride
Description: Antidepressant that is also effective in smoking cessation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Hydrochloride
Description: Antidepressant that is also effective in smoking cessation
Study: NCT06484712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic Resonance (SR)
Description: The system consists of six linear isolated stimulators (STMISOLA, Biopac Systems, Inc., Goleta, USA). The SR signal (Gaussian White Noise, zero mean) will be generated through a 16 bit PCI 6733 National Instruments multifunction data acquisition card by a custom LabView program. The stimulation sites include the ankle, lateral soleus, peroneus longus, and tibialis anterior muscles and the hip.
Study: NCT04801966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: 2 mg per day, continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: 60 mg/day for 21 days of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: 45 mg/twice a day, continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: 300 mg/day, continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 960 mg/twice per day, continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: 150 mg/twicce per day, continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: 450 mg/day, continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125 mg/day, day 1-21 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg/twice per day, continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: 600 mg/day, on day 1 -21 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150 mg twice/day, continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: 1 mg/day, on day 1 -28 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg IV once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg IV on Day 1 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV on day 1 of a 21 day cycle
Study: NCT04480203

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stressproffen cognitive based stress management
Description: The participants will download an app (Stressproffen 2A) with cognitive based stress management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stressproffen mindfulness based intervention
Description: The participants will download an app (Stressproffen 2B) with mindfulness based intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The participants will receive no app. (They will be able to download it after the end of the 3 year study).
Study: NCT06054932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LK101 injection
Description: LK101 administrated Q2W as the prime dose, and Q3W in the boost phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LK101 injection
Description: LK101 administrated QW as the prime dose, and Q3W in the boost phase
Study: NCT05096325

Intervention type: DEVICE
Intervention: YpsoPump® insulin pump system
Description: The subjects will receive a CE-certified mylife™ YpsoPump® insulin pump system that allows detailed logging of pressure data. Data will then be analysed in silico comparing the new occlusion detection algorithm with the common occlusion detection algorithm.
Study: NCT03933657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SoundBite™ Crossing System - Peripheral
Description: SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.
Study: NCT05100745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Device
Description: This device delivers ultrasound energy to the targeted area of the lower limb.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Therapeutic Device
Description: This device delivers ultrasound energy to the targeted area of the lower limb.
Study: NCT05531266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hUC-MSCs
Description: Participants will be treated with hUC-MSCs at a dose of 1×10\^6 /kilogram (kg) actual body weight at Screening for twice per week in 1-2 weeks and once a week in 3-4 weeks after being rolled into this study. At the same time, patients will be treated with glucocorticoids according to patients' condition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glucocorticoids
Description: Participants were treated with glucocorticoids only.
Study: NCT05104216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine
Description: receive a third dose of inactivated COVID-19 vaccine
Study: NCT06235411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin therapy
Description: Two administrations of psilocybin given 3 weeks apart. The treatment day will begin around 9 a.m. with a brief interview. Patients will be invited to relax and music will be played through speakers and headphones.~One 25 mg capsule of Psilocybin will be given approximately 30 minutes to 1.5 hours later.~The patient is accompanied throughout the session (minimum 6 hours depending on the effects felt). The patient will benefit from a preparation session the day before dosing, and an integration session the day after. Intensive relapse prevention program will be dispensed between the 2 dosing sessions (treatment as usual).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Psilocybin therapy
Description: Two administrations of psilocybin given 3 weeks apart. The treatment day will begin around 9 a.m. with a brief interview. Patients will be invited to relax and music will be played through speakers and headphones.~One 1 mg capsule of Psilocybin will be given approximately 30 minutes to 1.5 hours later.~The patient is accompanied throughout the session (minimum 6 hours depending on the effects felt). The patient will benefit from a preparation session the day before dosing, and an integration session the day after. Intensive relapse prevention program will be dispensed between the 2 dosing sessions (treatment as usual).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electroencephalogram
Description: * Rest EEG prior to first treatment administration~* EEG during first treatment administration~* Rest EEG during integration session after second treatment administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroencephalogram
Description: * Rest EEG prior to first treatment administration~* EEG during first treatment administration~* Rest EEG during integration session after second treatment administration
Study: NCT06263998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCP112
Description: NCP112 topical ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCP112
Description: NCP112 topical ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCP112
Description: NCP112 topical ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCP112
Description: NCP112 topical ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCP112
Description: NCP112 topical ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCP112
Description: NCP112 topical ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NCP112 Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NCP112 Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NCP112 Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NCP112 Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NCP112 Placebo
Description: Placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NCP112 Placebo
Description: Placebo comparator
Study: NCT06545773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root Canal Treatment with ProTaper Next Nickel-Titanium File (PTN)
Description: ProTaper Next (Dentsply Sirona) is a rotational system made of a nickel-titanium alloy called M-Wire. It has a rectangular cross-sectional design; thus, only two sides touch the root canal. Five files are available: X1 17/. 04, X2 25/.06, X3 30/. 07, X4 40/.06, and X5 50/.06. This file aggressively removes the coronal dentine of root canals due to its large taper. PTN nickel-titanium systemis used in root canal treatments to debride and shape the root canals.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root Canal Treatment withTruNatomy Nickel-Titanium File (TN)
Description: TruNatomy (Dentsply Sirona) is a heat-treated nickel-titanium system that consists of an orifice modifier, glide path, and shaping files. The TruNatomy Small, Prime, and Medium files have sizes of 20/.04, 26/.04, and 35/.04, respectively. It has a rectangular cross-section and a regressive taper. Its slim design allows for a conservative preparation of root canals and the preservation of the coronal dentine. TN nickel-titanium system is used in root canal treatments to debride and shape the root canals.
Study: NCT06305741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Managing Anxiety from Cancer (MAC)
Description: The intervention, MAC, is a seven-session (45-60 minutes per session) psychotherapy intervention delivered via videoconference.~and/or telephone by licensed social workers
Study: NCT06168734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime-taniborbactam
Description: Cefepime-taniborbactam administered 2.5g q8h intravenously (IV) over a 4-hour period for 7 days to 14 days at the investigator's discretion. Dose adjustments for renal function may apply.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem will be administered 2g q8h IV over 4 hours for 7 days to 14 days at the investigator's discretion. Dose adjustments for renal function may apply.
Study: NCT05988463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate Oral Product
Description: Artesunate capsules administered orally twice daily beginning at 10 mg for 4 weeks, followed by 20 mg for 4 weeks, and then 30 mg for 4 weeks.
Study: NCT06149650

Intervention type: DEVICE
Intervention: Shockwave Medical IVL System
Description: Comprehensive system consisting of generator, a connector cable and a single-use sterile catheter with integrated balloon for intravascular lithotripsy of peripheral artery calcification.
Study: NCT05024097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant (AB928)
Description: Patients will receive a radiation therapy dose of 25Gy in 5 fractions in combination with etrumadenant 150 mg orally, once daily as part of a continuous dose regimen.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Patients will receive a radiation therapy dose of 25Gy in 5fx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: After completing the radiation therapy, patients will receive FOLFOX regimen for 9 cycles in combination with etrumadenant and zimberelimab. All patients will be offered adjuvant zimberelimab for up to one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab (AB122)
Description: After completing the radiation therapy, patients will receive FOLFOX regimen for 9 cycles in combination with etrumadenant and zimberelimab. All patients will be offered adjuvant zimberelimab for up to one year.
Study: NCT06015503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLB1004
Description: PLB1004 is a capsule in the form of 80mg and 40mg.
Study: NCT05330702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xenogeneic Volume-Stable Collagen Matrix (VCMX) graft No Intervention: No Soft Tissue Augmentation
Description: Fibro-gide is the VCMX

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tuberosity Connective Tissue Graft (CTG)
Description: CTG will be taken from the patient's own mouth
Study: NCT04930159

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated group support
Description: Weekly group gatherings where content will alternate between group conversation and focused topics (e.g., treatment side-effects, mental health, family dynamics, nutrition, financial hardship) with facilitated discussion by a trained professional in nutrition, psychotherapy, cognitive behavioral therapy, or medicine. Each group will cycle through the same order of topics.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1:1 Peer Support
Description: 1:1 peer support via telephone or video either during or near a treatment visit. Call content will be focused on social support and driven by the needs of the participant.
Study: NCT06532864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Mawangdui Guiding Technique
Description: Nursing staff with experience in teaching Mawangdui Daoyin Exercise conducted the operation instruction on different floors. A feasibility assessment of the older adults was carried out by the nursing staff at the end of the teaching, and only after passing this assessment could the experimental part begin. The treatment group participated in five Mawangdui Daoyin Exercise sessions per week, each lasting approximately 45 minutes, and the exercises continued for 12 weeks.
Study: NCT05581303

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given by subcutaneous injection once every 12 weeks (Q12W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olpasiran
Description: Olpasiran given by subcutaneous injection Q12W.
Study: NCT04315233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib Dose Level 0 (starting dose) 200mg QD Dose Level 1A 400mg QD on Days 8-28 Dose Level 1B 200mg QD Dose Level 2 400mg QD on Days 8-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat Dose Level 0 (starting dose) 600mg/m2 daily for 5 days Dose Level 1A 600mg/m2 daily for 5 days Dose Level 1B 1000mg/m2 daily for 5 days Dose Level 2 1000mg/m2 daily for 5 days~\*Administration on 5 consecutive days is preferred. Administration within 7 days allowed as needed to accommodate holidays and infusion schedules.
Study: NCT06353126

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DEB-TACE
Description: DEB-TACE, or Drug-Eluting Bead Transarterial Chemoembolization, is a minimally invasive interventional radiology procedure primarily used in the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer. This procedure combines two treatment modalities: transarterial chemoembolization (TACE) and the use of drug-eluting beads (DEB).~During DEB-TACE, tiny beads loaded with chemotherapy drugs are injected directly into the blood vessels supplying the tumor in the liver. These drug-eluting beads gradually release chemotherapy agents, delivering a targeted and sustained dose directly to the cancerous tissue while minimizing systemic side effects. Additionally, the beads themselves act as embolic agents, blocking the blood flow to the tumor and causing ischemia, which further contributes to the destruction of the tumor cells.
Study: NCT06347055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Continuous theta burst rTMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Continuous theta burst rTMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Continuous theta burst rTMS
Study: NCT05051254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Esogastric pressure measurement
Description: Measurement of work of breathing and respiratory muscles strength using an esogastric catheter.~One measurement or before and after (6 months and 1 year) the initiation of a pharmacological treatment in order to assess the effect of the treatment on respiratory muscle function.
Study: NCT06640985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDX110 wound dressing system
Description: EDX110 is a dressing system comprising two layers that allows the generation of nitric oxide (NO) in situ, enables adequate moisture management and facilitates debridement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EDX110 wound dressing system
Description: EDX110 is a dressing system comprising two layers that allows the generation of nitric oxide (NO) in situ, enables adequate moisture management and facilitates debridement
Study: NCT06562153

Intervention type: OTHER
Intervention: Neuroimaging with Magnetic Resonance Imaging (MRI)
Description: MRI will be used to observe brain states over time.
Study: NCT05365646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aids equipped with motion sensing abilities
Description: Participants will wear hearing aids that will assess their movement, and fall risk.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aids equipped with motion sensing abilities
Description: Participants will wear hearing aids that will assess their movement, and fall risk.
Study: NCT05681468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Keto-SAT
Description: Nutrition counselling focused on Keto diet (saturated fat).~10% TE as carbohydrate (mainly from vegetables and whole grain products), protein between 20-30% TE and fat between 60-70%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Keto-CAN
Description: Nutrition counselling focused on Keto diet (unsaturated fat).~10% TE as carbohydrate (mainly from vegetables and whole grain products), protein between 20-30% TE and fat between 60-70%.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LFD
Description: Nutrition counselling focused on low-fat diet.~30% total energy (TE) as fat, 50% TE as carbohydrates (primarily whole grains) and 17-20% TE protein (mainly lean sources).
Study: NCT05219292

Intervention type: OTHER
Intervention: Active music therapy
Description: Active music therapy is not a musical learning process. The restrictive character of classical respiratory rehabilitation will be alleviated by the playful aspect and the pleasure generated by the sessions, which will facilitate the commitment of the patients in their post-transplant respiratory rehabilitation.~The recorder was chosen among other wind instruments for several reasons:~* Its use is simple,~* It acts as an oscillating exhalation resistance device that generates a positive expiratory pressure (auto-PEP) produced by this wind instrument allows to obtain conditions similar to the treatment performed by a flutter (classical respiratory rehabilitation), a pressure on the expiratory flow with the obtaining of an oscillating effect during the trills, an increase of the respiratory capacities,~* The characteristics of the sound it produces (duration, intensity, timbre and frequency) will generate auditory feedback allowing patients to become aware of their breathing patterns.

Intervention type: OTHER
Intervention: Questionnaires
Description: We chose the HAD (Hospital Anxiety and Depression Scale) to assess anxiety and depression. This test is a reference test, often used in studies of transplant patients. The results obtained in previous studies allowed us to create our hypotheses.~To measure pain we chose the visual analogue scale (VAS). This reference test is often used in pain studies. It has the advantage of being simple to perform and easy to understand.~Quality of life will be assessed using the SF-12 (Short Form 12 Health Survey Questionary). We consider it to be simple and easy for patients to understand.
Study: NCT06400459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVW-1001 Ophthalmic Eyelid Wipe 0.1%
Description: IVW-1001 Ophthalmic Eyelid Wipe 0.1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVW-1001 Ophthalmic Eyelid Wipe 0.2%
Description: IVW-1001 Ophthalmic Eyelid Wipe 0.2%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IVW-1001 Placebo
Description: IVW-1001 Placebo
Study: NCT06051123

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Participants will be taking 1 sachet a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be taking 1 sachet a day.